
1. malar res treat. 2018 may 2;2018:7071383. doi: 10.1155/2018/7071383. ecollection 
2018.

effects drug policy changes evolution molecular markers plasmodium
falciparum resistance chloroquine, amodiaquine, sulphadoxine-pyrimethamine
in south west region cameroon.

moyeh mn(1)(2), njimoh dl(1), evehe ms(2)(3), ali im(2)(4), nji am(2)(3), nkafu
dn(1), masumbe pn(2)(3), barbara at(2)(3), ndikum vn(2), mbacham wf(2)(3).

author information: 
(1)department biochemistry & molecular biology, university buea, pb 63,
buea, cameroon.
(2)laboratory public health research biotechnologies, university yaoundé
i, bp 8094, yaoundé, cameroon.
(3)department biochemistry, university yaoundé i, pb 812, yaoundé,
cameroon.
(4)department biochemistry, university dschang, bp 67, dschang, cameroon.

background: result spread parasites resistant antimalarial
drugs, malaria treatment guidelines cameroon evolved nonartemisinin
monotherapy artemisinin-based combination therapy. aim study was
to assess effect therapy changes prevalence molecular
markers resistance 2003 2013 mutengene, cameroon.
methodology: dry blood samples (collected 2003-2005 2009-2013) used
for parasite dna extraction. drug resistance genes amplified pcr and
hybridized oligonucleotide probes subjected restriction digestion. the
prevalence individual marker polymorphisms haplotypes compared in
these two study periods using chi square test.
results: alleles conferring resistance 4-aminoquinolines pfcrt 76t 
pfmdr1 86y, 184f, 1246y genotypes showed significant reduction 97.0% 
66.9%, 83.6% 45.2%, 97.3% 56.0%, 3.1% 0.0%, respectively (p < 0.05).
no difference observed snps associated antifolate drugs resistance
51i, 59r, 108n, 540e (p > 0.05). haplotype analysis pfmdr1 gene showed 
a reduction yfd 75.90% 42.2%, p < 0.0001, increase the
nyd (2.9% 30.1%;  p < 0.0001).
conclusions: results indicated gradual return 4-aminoquinoline
sensitive genotype antifolate resistant genotypes increased to
saturation.

doi: 10.1155/2018/7071383 
pmcid: pmc5954917
pmid: 29854394 

